Previous 10 | Next 10 |
The biotech sector is also presenting exciting opportunities for investors. Many of the best biotech companies have both strong drug candidate pipelines and winning drugs already on the market. The COVID-19 pandemic has also created massive opportunities for biotechnology companies. According...
Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study PR Newswire DUBLIN , Jan. 10, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced enrollment of th...
Theravance Biopharma to Present at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire DUBLIN , Jan. 5, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a biopharmaceutical company primarily focused on the discovery, development and comme...
Gainers: Inotiv (NASDAQ:NOTV) +13%, Theravance Biopharma (NASDAQ:TBPH) +11%, Biofrontera (NASDAQ:BFRA) +11%, Dare Bioscience (NASDAQ:DARE) +10%, Stereotaxis (NYSE:STXS) +8%. Losers: Radius Health (NASDAQ:RDUS) -43%, Ensysce Biosciences (NASDAQ...
Theravance Biopharma (NASDAQ:TBPH) is trading ~2.7% lower in the pre-market after announcing its decision to voluntarily discontinue the Phase 2 study of izencitinib in Crohn’s disease. The company had anticipated topline results from the trial in Q1 2022. Theravance (TBPH) h...
Seth Klarman’s 13F portfolio value decreased from $12.33B to $10.88B this quarter. Baupost Group increased Liberty SiriusXM, Theravance Biopharma, and Joby Aviation while decreasing eBay, Willis Towers Watson, International Flavors & Fragrances, and PG&E. The portfo...
Seth Klarman's Baupost fund initiates position in Dropbox (NASDAQ:DBX) with 9.28M shares and Outbrain (NASDAQ:OB) with 0.8M shares, according to its latest 13F filing. Boost stakes in Theravance Biopharma (NASDAQ:TBPH) and Verint Systems (NASDAQ:VRNT). Baupost made a private placement in...
Image source: The Motley Fool. Theravance Biopharma, inc (NASDAQ: TBPH) Q3 2021 Earnings Call Nov 3, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Theravance Biopharma, inc (TBPH) Q3 2021 Earnings Call Transcript ...
Theravance Biopharma, Inc. (TBPH) Q3 2021 Earnings Conference Call November 3, 2021 17:00 ET Company Participants Gail Cohen - Vice President, Corporate Communications Rick Winningham - Chief Executive Officer Rhonda Farnum - Senior Vice President, Commercial and Medical Affairs Rick Graham -...
Theravance Biopharma (NASDAQ:TBPH): Q3 GAAP EPS of -$0.48 beats by $0.08. Revenue of $13.2M (-27.7% Y/Y) misses by $1.49M. Press Release For further details see: Theravance Biopharma EPS beats by $0.08, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...